New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 14, 2026

Back to the front page

From X

@StableBread

Fajasy on X

Agility Robotics $AGLT, the maker of the Digit humanoid robot, now expects early access to Digit 5, its next-generation model, to begin in H1 2027. Digit 5 would reach early customers in December, President Daniel Diez told Forbes in August. In my September 6 deep dive, I called the December date the one to watch. Agility gave the new timeline in its Q3 financials, filed November 13 alongside the final 10-Q of Churchill Capital Corp XI, the SPAC it merged with on November 4. Holders of 61.5% of the SPAC's public shares redeemed them for ~$10.29/share, taking ~$261.8M out of the trust. So Agility netted ~$334.1M from the deal, plus the $100M of SAFEs it raised in July. In the S-4 (the merger filing), the no-redemption case came to ~$576M. The Q3 financials also show: → Cash: $64.9M as of September 30, down from $103.0M at the end of 2025, even after the $100M of SAFEs. → Burn: $131.6M of operating cash outflow in the first nine months, up 87% y/y, plus $6.8M of capex. → Revenue: $0.36M in the first nine months, down 79% y/y, since 2025's one-time robot sales didn't repeat. Add the deal's ~$334.1M to September 30 cash, and Agility has ~$399M. At the first nine months' pace of ~$184M/year, including capex, the ~$399M lasts a little over two years, with Digit 5's rollout now running through 2027. The closing release did add two customer updates: $GXO, the logistics company, will deploy Digit at two more U.S. sites starting in early 2027, and $AGCO, the farm equipment maker, will pilot Digit in 2027, with no order sizes given. At $7.36/share, $AGLT's market cap is ~$2.26B on ~307M shares, counting ~61.0M options and RSUs and 4.2M warrants. My deep dive valued the 1,000-robot Digit 5 order book alone at $4.69-7.66/share, at 10-20x its ~$100M of yearly revenue plus cash. Redone with the actual cash and share count, the range is closer to $4.55-7.81/share, and $AGLT now trades inside the range. $AGLT also trades 28% below the ~$10.29/share redeeming holders received, and below the ~$7.72/share the July SAFE investors paid. My deep dive said I'd only consider buying after the post-close washout, once the lock-up supply clears and Digit 5's ramp is clearer. The washout came, but the other two conditions haven't: 1) Lock-up supply: Agility's existing holders and the sponsor stay locked up until early May 2027, and the PIPE's 20.1M shares, more than the ~16M public shares left after redemptions, are being registered for resale. 2) Digit 5: Early access now starts in H1 2027 instead of December, with wider availability over the following 6-9 months.
@ACapitalLP

A Capital on X

Moves like this $ADIG should not happen absent some genuinely unforeseen event or force majeure. If a public company is even remotely transparent with investors, expectations shouldn’t be so far removed from reality that a single earnings report wipes out 40–50% of its market cap. Granted, this is probably more common in smaller companies with limited analyst coverage, but if I were a public company CEO and this happened on my watch, I’d consider it a serious failure of investor communication and expectation management…
@StableBread

Fajasy on X

Reviva Pharmaceuticals $RVPH now plans to apply to relist on Nasdaq in H1 2027, and its December 18 annual meeting asks shareholders to approve a reverse split of up to 1-for-100 to get there, nine months after its last one. Nasdaq suspended $RVPH on May 14 for trading below its $1.00 minimum bid price, and the stock has traded on the OTC since. At $0.35/share, $RVPH's market cap is ~$4.6M against $17.5M of cash as of September 30, or ~26% of its ~$1.33/share of cash. In my August 20 update, I wrote that steady ATM dilution looked paused, since Reviva said it doesn't expect to use its $50M ATM (selling new shares straight into the market) while it's quoted on the OTC. $RVPH's Q3 10-Q, filed November 13, says the same, and adds that the shelf registration behind the ATM expires February 13, 2027. And a company Reviva's size (under $75M of public float) needs an exchange listing to file a new shelf. RECOVER-2, the second Phase 3 trial of Reviva's schizophrenia drug brilaroxazine, plus the approval filing will cost $50-55M, CEO Laxminarayan Bhat said on an April fireside chat, about 3x Reviva's cash. The 10-Q says Reviva has no committed external sources of capital, and the Q3 earnings release still lists partnering as "pursuing partnership opportunities." So I read the reverse split and the relisting as the end of the pause in dilution: Back on Nasdaq, Reviva could sell stock again, through a new shelf or a public offering, to cover most of the $50-55M before RECOVER-2 starts. Cash fell $2.4M in Q3, and Reviva still says the $17.5M covers outlays "into the third quarter of 2027," close to the "into July 2027" it gave in August. The U.S. patent office also granted Track One priority examination to the patent application on a new formulation of brilaroxazine, which could extend the drug's protection to 2046. Track One aims for a final decision within ~12 months, and the decision can be a rejection.

Investor Letters

All letters

Q3 Earnings Updates

Q3 updates cover Crocs, Entravision and Fiserv beats, coal and oil weakness, and Xerox’s sharp decline, testing the underlying cases for…

CROX $7.5BEVC $874M
Hidden Rock Capital's Newsletter 1 click

The Spy Who Shagged The Market

Nvidia’s leadership scandal puts its AI-market role under scrutiny, with comparisons to AIG’s pre-GFC liquidity influence.

NVDA $3.9TAIG $43B
WHAT ARE WE DOING? “Contrarians At The Gate” 4 clicks

Is Nebius Fucked?

Nebius’ Q3 beat relied on $325 million of one-off partnership fees as it raised 2027 CapEx to $40–45 billion and may need $6–11 billion of…

NBIS $32B
Daniel Romero 6 clicks

Qualcomm Custom ASICs?

Qualcomm’s Alphawave SerDes, CPU cores and HBC could support custom AI ASICs as hyperscalers build heterogeneous fleets beyond GPUs.

QCOM $185B
Chipstrat 4 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 88 of 294

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.